Showing results (531-540 of 558) with videos related to

Sort By:
Pageof 56
International Journal of Cancer|November 9, 2021
The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from IndiaGeorge Abraham, Vanita Noronha, Senthil Rajappa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2025
Presentation and outcomes of second primary malignancies (SPMs) in locally advanced oral cavity squamous carcinoma (LA-OSCC): Secondary analysis of a phase III randomised control trial (NCT00193843)Sarbani Ghosh Laskar, Sahil Sood, Abhishek Chatterjee, et al.
Blood Cancer Journal|April 24, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
The Lancet. Oncology|May 3, 2025
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of CancerFábio Cardoso Borges, Winette T A van der Graaf, Robbe Saesen, et al.
Indian Journal of Cancer|March 9, 2026
Cetuximab in platinum-ineligible patients with locally advanced squamous cell carcinoma of the head and neck: Consensus from IndiaAgarwala Vivek, Aggarwal Shyam, Agrawal Shyam, et al.
JAMA|March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialRobert Haddad, Jérôme Fayette, Maria Teixeira, et al.
South Asian Journal of Cancer|December 22, 2025
Patterns of Failure in Head and Neck Carcinoma of Unknown Primary: Insights from a Tobacco-Associated Cancer CohortSarbani Ghosh Laskar, Jifmi Jose Manjali, Ashwini Budrukkar, et al.
Journal of Medicinal Chemistry|April 10, 2018
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234Krisztina M Papp-Wallace, Nhu Q Nguyen, Michael R Jacobs, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
South Asian Journal of Cancer|July 14, 2022
Ramucirumab in Indian Patients with Advanced Gastric Cancer-Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, et al.
Pageof 56